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Repression of viral gene expression
CCAAT displacement proteingalovirus (HCMV) productive infection is dependent on the major immediate
early (MIE) genes ie1 and ie2. Several putative binding sites for CCAAT displacement protein (CDP or CUX1)
were identiﬁed within the MIE promoter/regulatory region. Binding assays demonstrated binding of CUX1 to
MIE-region oligonucleotides containing the CUX1 core binding sequence ATCGAT and mutagenesis of this
sequence abrogated CUX1 binding. Furthermore, CUX1 repressed expression of a luciferase reporter cons-
truct controlled by the MIE promoter, and mutation of CUX1 binding sites within the promoter diminished
this repressive function of CUX1. In the context of virus infection of HEK293 cells transfected with the CUX1
expression vector, CUX1 showed evidence of association with the HCMV MIE regulatory region and inhibited
the capacity of the virus to express ie1 and ie2 transcripts, suggesting that this cellular factor regulates MIE
gene expression following virus entry. These data identify a role for CUX1 in repressing HCMV gene
expression essential for initiation of the replicative cycle.
© 2008 Elsevier Inc. All rights reserved.Introduction
Human cytomegalovirus (HCMV) is a betaherpesvirus that infects a
majority of the world's population. Productive HCMV infection
generally results in mild or clinically inapparent disease in most
immunocompetent individuals but infection of the fetus during
pregnancy can lead to devastating consequences including still birth,
mental retardation and hearing impairment (Boppana et al., 2005;
Pass, 2005; Yow et al., 1988). Host immune-mediated resolution of
productive infection does not result in complete clearance of the virus
from the body. Rather, the virus is able to establish a lifelong latent
infection in primitive hematopoietic cells, including CD34+ cells and
lineage committed myeloid progenitor cells and monocytes (Mocarski
et al., 2007). During latency, the viral genome is maintained in a
circular episomal conﬁguration (Bolovan-Fritts et al., 1999) in a small
proportion of cells at a level of 2–10 copies per cell (Slobedman and
Mocarski,1999), viral gene expression is restricted, and infectious virus
is not detectable (Mocarski et al., 2007). Periodically, the virus is able to
reactivate from latency, resulting in the synthesis of new, infectious
virus. Reactivation occurs in response to unknown stimuli, but is linked
to myeloid cell differentiation and growth or pro-inﬂammatoryestmead Millennium Institute,
98459100.
(B. Slobedman).
l rights reserved.cytokines (Hahn et al., 1998; Taylor-Wiedeman et al., 1994) or culture
of cells under conditions of allogeneic stimulation (Soderberg-Naucler
et al., 1997). Virus reactivation in immunosuppressed individuals such
as allogeneic transplant recipients causes signiﬁcant morbidity and
mortality as a consequence of disseminated infection and disease
involving multiple organs including the lung, liver, eye and gastroin-
testinal tract (Mocarski et al., 2007).
During productive infection of permissive cell types viral gene
expression occurs in an ordered cascade, of which a group of genes
termed immediate early (IE) genes are the ﬁrst to be expressed after
virus entry. IE genes are expressed in the absence of prior de novo viral
protein expression, and the most prominent expression at IE times
post-infection of permissive cells occurs from the major immediate
early (MIE) locus (DeMarchi et al., 1980; Wathen et al., 1981). The MIE
region encompasses two differentially spliced transcripts with novel
exons ie1 (UL123) and ie2 (UL122), that encode IE72 and IE86 proteins,
respectively. This region also encodes a number of additional proteins.
The MIE gene products are derived from a single alternately spliced
transcript originating from a single transcriptional start site (Stenberg
et al., 1985). The MIE regulatory region that controls expression of ie1/
ie2 genes consists of several elements including a promoter, enhancer,
unique region and distal modulator, which extend approximately
1150 bp upstream of the transcription start site (Meier and Stinski,
1996). Expression ofMIEpromoter-driven geneproducts are critical for
efﬁcient activation of the replicative cycle in permissive cells, as ie2 is
essential for virus replication (Marchini et al., 2001) and at low
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replicative cycle (GawnandGreaves, 2002;Greaves andMocarski,1998).
In contrast to productive infection, latent infection is characterised
by highly restricted viral gene expression with silencing of the MIE
promoter-driven ie1/ie2 genes, and it has therefore been hypothesised
that this repression may be an important step in the establishment or
maintenance of latency in hematopoietic cells (Mendelson et al., 1996;
Murphy et al., 2002; Taylor-Wiedeman et al., 1994). In this respect,
several cellular proteins known to act as repressors have been
implicated as possible negative regulators of MIE gene activity
(Sinclair and Sissons, 2006). These include transcription factors such
as Ets-2 repressor factor (ERF) and Yin Yang 1 (YY1), which have been
shown to repress the MIE regulatory region in transient transfection
assays of non-permissive Ntera2 D1 (T2) cells (Bain et al., 2003; Liu et
al., 1994), and also human Daxx (hDaxx) which can function to repress
MIE gene expression (Preston and Nicholl, 2006; Woodhall et al.,
2006). Chromatin modiﬁcation enzymes appear important for this
phenotype as the mechanism of action of ERF has been shown to
involve the recruitment of histone deacetylases (HDACs) to the MIE
regulatory region resulting in differentiation-dependent regulation of
the MIE promoter (Wright et al., 2005). YY1 has also been shown to
interact with HDACs (Yang et al., 1997) and hDaxx-mediated
repression correlates with a repressive chromatin structure around
the MIE promoter (Woodhall et al., 2006).
The CCAAT displacement protein (CDP or CUX1) is a member of the
conserved CDP/Cut family of homeoproteins found in higher order
eukaryotes (Nepveu, 2001). CUX1 is a transcription factor expressed in
a wide range of cells where it predominantly exhibits repressive
activity (Mailly et al., 1996; Skalnik et al., 1991; van Gurp et al., 1999),
although it has also been shown to be an activator of transcription in
some cases (Harada et al., 2008; Truscott et al., 2007; Truscott et al.,
2008; Truscott et al., 2003). CUX1 may control proliferation and
differentiation (Luo and Skalnik, 1996; van Gurp et al., 1999; Vanden
Heuvel et al., 1996), and plays an important regulatory role during
myelopoiesis (Friedman, 2002; Friedman, 2007; Khanna-Gupta et al.,
2001; Skalnik et al., 1991). CUX1 loses its DNA binding and repressive
phenotype when progenitors differentiate into monocytes and
macrophages (Martin-Soudant et al., 2000; Marziali et al., 1999).
Transcriptional repression by CUX1 is thought to involve both inhi-
bition of RNA polymerase II by occupying sites otherwise bound by
activating factors (Barberis et al., 1987; Luo and Skalnik, 1996; Mailly
et al., 1996), recruitment of histone methyltransferases (Nishio and
Walsh, 2004), and like YY1, by recruitment of HDACs facilitating the
formation of heterochromatin (Li et al., 1999; Mailly et al., 1996).
In this study we report that the HCMV MIE regulatory region
contains an unusually high number of putative binding sites for CUX1
and show that this transcription factor is able to bind to core
sequences within the MIE regulatory region in vitro. We also show
that overexpression of CUX1 in HEK293 cells results in signiﬁcant
repression of luciferase expression driven by the MIE promoter/
regulatory region, and that mutation of identiﬁed CUX1 binding sites
within this region diminishes the ability of CUX1 to repress MIE
promoter activity. Importantly, following virus infection, CUX1
showed evidence of association with the MIE regulatory region and
also inhibited the expression of HCMV ie1 and ie2, suggesting that this
transcription factor may act as a regulator of HCMV gene expression
required to initiate the replicative cycle.
Results
Identiﬁcation of putative CUX1 binding sites in HCMV
Full length CUX1 contains four DNA binding domains and
different potential binding sequences have been reported (Andres
et al., 1994; Auﬁero et al., 1994; Harada et al., 1995; Moon et al.,
2001; Nirodi et al., 2001). To determine the number of potentialCUX1 binding sites within the HCMV major immediate early (MIE)
gene regulatory region, motifs that had exact or similar matches to
the CUX1 core consensus binding sites were mapped against a
2.1 kbp sequence encompassing the MIE regulatory region using the
software tool MatInspector (Genomatix Software, Munchen, Ger-
many). From this analysis, 13 putative distinct human CUX1 binding
sites were identiﬁed (Fig. 1A). Three were located in the enhancer
region, four in the unique region, four in the distal modulator and
two upstream of the distal modulator. Nine putative binding
sequences had core and matrix similarity scores of greater than or
equal to 0.8 which is indicative of a strong binding potential to CUX1
while four had scores below 0.8, but greater than 0.7, which may also
bind to CUX1.
The occurrence of putative binding motifs for transcription factors
may occur due to random variation in genomic sequence; different
transcription factor motifs occur randomly with different frequencies,
depending on the nucleotide sequence. To ascertain whether the
number of putative binding sites for CUX1 found in theMIE regulatory
region was a non-speciﬁc feature of the viral genome, or whether it
was restricted to speciﬁed regions of the viral genome, the entire
genomic sequence of HCMV strain AD169 (accession x17403) was
analysed for these motifs, and the number of binding sites was deter-
mined for 2000 bp segments across the HCMV genome (Fig. 1B). This
analysis revealed that the number of putative CUX1 binding sites
identiﬁed in the MIE regulatory region was not a common feature of
the remainder of the viral genome. The majority of the viral genome
contained very fewputative CUX1 binding sites, with a vastmajority of
the 2000 bp genomic segments analysed containing 0, 1 or 2 putative
binding sites. Notable exceptions being the segment including theMIE
regulatory region (13 binding sites) and a region encompassingUL108–
UL110 (13 binding sites). This analysis suggested that random
occurrences of these motifs were unlikely to account for the relatively
large number of putative binding sites within or proximal to the MIE
regulatory region.
Detection of sequences within the HCMV MIE regulatory region that bind
to CUX1
To test the identiﬁed sequences from the MIE regulatory region
for CUX1 binding capability, an in vitro binding assay was performed.
A subset of the sequences detected in our analysis of putative
transcription factor binding sites of the MIE region were selected for
further analysis and oligonucleotides encompassing these putative
binding domains were synthesized. The eight sequences selected for
further analysis were those with the highest degree of match with
the core motifs reported to bind CUX1 (i.e. eight sequences with the
highest core and matrix similarity scores). These oligonucleotides
were termed CMV 1 (core and matrix similarity scores: 1 and 0.96,
respectively), CMV 2 (1 and 0.95), CMV 3 (1 and 0.81), CMV 4 (1 and
0.92), CMV 5 (1 and 0.80), CMV 6 (1 and 0.77), CMV 7 (0.96 and 0.73)
and CMV 8 (0.93 and 0.94). In addition to these 8 HCMV sequences,
two positive control consensus CUX1 binding human sequences were
included. These latter sequences were chosen based on published
studies reporting the sequences that CUX1 binds with greatest
afﬁnity (Moon et al., 2001; Nirodi et al., 2001). Initial experiments in
HEK293 cells indicated that basal levels of CUX1 were too low to
carry out the in vitro transcription factor binding assays. Therefore,
HEK293 cells were transfected with a CUX1 expression vector
encoding the full length 5.2 kb cDNA for CUX1 driven by the ade-
novirus type 5 major-late promoter (Neufeld et al., 1992). Efﬁciency
of transfection of HEK293 cells was routinely greater than 90% (data
not shown). At 48 h post-transfection nuclei were puriﬁed and lysed
in the presence of a protease inhibitor cocktail. Biotin end-labelled
double-stranded oligonucleotides containing each of the 8 putative
MIE-region CUX1 binding sites or 2 known human CUX1 binding
sites were incubated with or without nuclear protein extract, and
Fig. 1. Putative CUX1 binding sites in HCMV. (A) Map showing the location of the putative CUX1 binding sites identiﬁed within a 2.1 kbp sequence of the HCMV genome (strain
AD169) encompassing the MIE regulatory region, which includes the ie1/ie2 promoter, enhancer, unique region and distal modulator. Arrow indicates the transcriptional start site at
nucleotide position 173,730. Filled ovals indicate putative CUX1 binding sites identiﬁed by MatInspector software to have high core and matrix similarity values (≥0.8) while open
ovals indicate putative CUX1 binding sites with core and matrix similarity values b0.8 but N0.7. (B) Number of putative CUX1 binding sites counted for 2000 bp segments across the
HCMV strain AD169 genome. A schematic representation of the HCMV AD169 genome is aligned beneath binding site counts, with the position of the major immediate early region
(MIE) shown. Also shown are major features of the genome including the terminal repeat long and short segments (TRL and TRS, respectively), internal repeat long and short
segments (IRL and IRS, respectively), and the unique long (UL) and unique short (US) segments.
216 J.L. Stern et al. / Virology 378 (2008) 214–225then bound to streptavidin coated wells. After washing away un-
bound nucleotides and protein, wells were stained using an antibody
speciﬁc for CUX1, followed by colorimetric detection.
In replicate experiments, both of the positive control consensus
CUX1 binding human sequences showed higher levels of absorbance
than a negative control which consisted of all reaction components
but without the addition of any oligonucleotide sequences (Fig. 2A).
In addition, when the positive control human cellular sequences
were tested in the absence of nuclear extracts, the level of absorb-
ance dropped to a level similar to that of the negative control.
Results for three (CMV 1, CMV 2, and CMV 4) of the eight HCMV
sequences gave positive staining of similar intensity to that of the
positive control sequences, while the other ﬁve HCMV sequences
were negative. The positions of the three HCMV MIE-region
oligonucleotides which demonstrated positive binding to CUX1 are
illustrated in Fig. 2B. CMV 1 is an oligonucleotide sequence located
from −736 bp to −758 bp upstream of the MIE transcription start site
within the unique region. CMV 4 is an oligonucleotide sequence
located in the distal modulator −1006 bp to −1034 bp upstream of
the start site. CMV 2 is an oligonucleotide sequence −1245 bp to
−1267 bp upstream of the start site. Although the ﬂanking sequences
outside the core motifs contained within these oligonucleotides
varied signiﬁcantly, the oligonucleotides that gave positive signals in
the binding assay (CMV 1, CMV 2 and CMV 4) all contained exact
matches for one of the predicted CUX1 core binding site sequence
(ATCGAT) (Moon et al., 2001), and were also those which yieldedhighest core and matrix similarity scores as a predictor of CUX1
binding potential.
To determine whether the CUX1 core binding sequence ATCGAT
was required for binding to CUX1 to the MIE region, this binding site
wasmutated in oligonucleotides CMV1, CMV2 and CMV4by reversing
the positions of the 2 nucleotides A and T to generate oligonucleotides
CMV 1Mut, CMV 2Mut and CMV 4Mut. Themutated oligonucleotides
were then compared with their respective unmodiﬁed parent oligo-
nucleotide for ability to bind to CUX1 using an in vitro binding assay. As
before, CMV 1, CMV 2 and CMV 4 demonstrated binding comparable to
that of the 2 positive control human sequences (Fig. 2C). In contrast,
mutation of the CUX1 core binding sequence in all 3 viral oligonucleo-
tides abrogated this binding capacity, with absorbance readings
reduced to a level comparable to those of the negative controls;
whichwere reactions eitherwithout oligonucleotides,without nuclear
extract, or inclusion of an HCMV oligonucleotide not containing any
known CUX1 binding motif.
To determine the speciﬁcity of the three CUX1 binding sites iden-
tiﬁed within the MIE region, the parent oligonucleotides were
competed against speciﬁc and non-speciﬁc unlabelled competitors
using the in vitro binding assay (Fig. 3). In replicate experiments, the
addition of increasing amounts of speciﬁc unlabelled competitors
leads to statistically signiﬁcant reductions in staining intensity when
compared with staining of labelled oligonucleotides without the addi-
tion of competitors. In addition, when unlabelled non-speciﬁc compe-
titors were added, no statistically signiﬁcant change in signal intensity
Fig. 2. Binding of CUX1 to sites within the MIE regulatory region identiﬁed by trans-
cription factor binding assay. (A) Graph depicting the binding activity of double-
stranded oligonucleotide sequences to CUX1 using a colorimetric transcription factor
binding assay. The average absorbance readings at 450 nm from three independent
replicate experiments utilising extracts from CUX1 expressing HEK293 cells incubated
with 10 pmol of oligonucleotides containing putative CUX1 binding sites from the HCMV
MIE regulatory region (CMV 1–CMV 8) or consensus human CUX1 binding sequences
(POS 1 and POS 2) are shown, with a negative control (No oligo) in which no
oligonucleotides were added to the reaction mixture. Black bars show absorbance
readings when nuclear extract from 2.5×105 CUX1 expressing HEK293 cells was added,
while the grey bars show readings for the same sequences when nuclear extracts were
omitted. Signiﬁcant differences to the no extract control were determined using a
1-tailed, paired Students t-test and are indicated as follows: ⁎Pb0.05. Error bars are
±standard error of the mean (SEM). (B) Location of oligonucleotide sequences (CMV 1,
CMV 2 and CMV 4) within or proximal to the MIE regulatory region which exhibited
binding to CUX1. (C) Effect of mutation of CUX1 binding sites within the MIE regulatory
region using a colorimetric transcription factor binding assay. Oligonucleotides con-
taining putative CUX1 binding sites from the HCMVMIE regulatory region (CMV 1, CMV
2 and CMV 4) or these oligonucleotides with a 2 base pair swap within the putative
CUX1 binding site (CMV 1 Mut, CMV 2 Mut and CMV 4 Mut). Positive controls were
oligonucleotides with consensus human CUX1 binding sequences (POS 1 and POS 2)
and negative controls were reactions with no addition of oligonucleotides (No oligo),
reactions using an HCMV MIE-region oligonucleotide containing no CUX1 binding site
(Neg) and reactions where nuclear extracts were omitted. The average absorbance
readings at 450 nm from four independent replicate experiments are shown. Signiﬁcant
differences to no extract controls were determined using a 1-tailed, paired Students
t-test and are indicated as follows: ⁎Pb0.05. Error bars are ±standard error of the
mean (SEM).
Fig. 3. Binding of CUX1 to sites within the MIE regulatory region in the presence of
competitor binding sequences. Graphs depicting the binding activity of double-
stranded oligonucleotide sequences of the putative CUX1 binding sites (A) CMV 1, (B)
CMV 2 and (C) CMV 4 (10 pmol of each) incubated with unlabelled speciﬁc competitors
at increasing concentrations and unlabelled non-speciﬁc competitors using a colori-
metric transcription factor binding assay. Non-speciﬁc competitors were an unlabelled
HCMV MIE-region oligonucleotide containing no CUX1 binding sites (Neg) at a
concentration of 100 pmol, and 100 pmol of an unlabelled mutant oligonucleotide with
an A–T base swap within the putative CUX1 binding site in each of the 3
oligonucleotides (CMV 1 Mut, CMV 2 Mut and CMV 4 Mut). Negative control was a
reaction where extract was omitted (No Extract). The mean absorbance readings at
450 nm normalised to reactions where no competitor was added from three to ﬁve
independent experiments are shown. Signiﬁcant differences were determined using a
1-tailed, paired Students t-test and are indicated as follows: ⁎Pb0.05, ⁎⁎Pb0.005,
⁎⁎⁎Pb0.0005, ⁎⁎⁎⁎Pb0.00005, ⁎⁎⁎⁎⁎Pb0.000005. Error bars are ±SEM.
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CMV 2 and CMV 4. It was concluded that the sequence ATCGAT
identiﬁed within 3 regions of the MIE regulatory region facilitated the
binding of CUX1.
Fig. 4. Overexpression of CUX1 represses transcription driven by the HCMV MIE
regulatory region. (A)Western blot of nuclei extracted from untransfected HEK293 cells,
or HEK293 cells transfected with either a CUX1 expression construct (CUX1) or its
parent vector (pMT). Nuclear proteins were separated by SDS-PAGE and transferred to
PVDF membrane before incubation with an anti-CUX1 antibody and binding visualised
with ECL. The membrane was subsequently stripped of bound antibody and re-probed
for the housekeeping gene GAPDH to assess any differences in loading between wells.
(B) HEK293 cells transfected with a luciferase expression construct driven by a 2.1 kb
region of the HCMV genome containing the MIE regulatory region (pMIEP) or a mutant
construct whereby the three CUX1 binding sequences containing the coremotif ATCGAT
were mutated to TACGAT (pMIEPmut), were co-transfected with either a CUX1
expression construct (CUX1) or parental construct (pMT). Cells were also transfected
with a β-galactosidase expressing vector under the control of the SV40 promoter, which
was used to normalise between treatments for differences in transfection efﬁciency and
endogenous differences in global transcription. Luciferase expression levels are shown
relative to parental vector-transfected cells from 3 independent replicate experiments.
Signiﬁcant differences were determined using a 1-tailed, paired Students t-test and are
indicated as follows: ⁎Pb0.05, ⁎⁎Pb0.005. Error bars are ±SEM.
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region
Major immediate early gene expression is an essential feature of
successful viral replication, being required to initiate the characteristic
gene expression cascade. Failure to express ie1 and ie2 genes from the
MIE region results in a failure to initiate a productive infection
(Marchini et al., 2001; Mocarski et al., 1996). It has also been hypo-
thesised that this failure may be important in the establishment of
latency (Shelbourn et al., 1989). To assess whether CUX1 inhibited
transcription driven by the MIE promoter, a luciferase reporter vector
was constructed, with luciferase expression driven by the MIE promo-
ter encompassed within a 2.1 kbp sequence containing the MIE
regulatory region. This reporter vector (pMIEP) was transfected into
HEK293 cells, together with a CUX1 expression vector (pMT2-CDP),
and a β-galactosidase expression vector driven by the SV40 promoter
to normalise for endogenous differences in basal transcription and
transfection efﬁciency between treatments. The SV40 promoter does
not contain any known motifs for CUX1 binding and was not itself
affected by transfection with the CUX1 expression vector (data not
shown). In parallel, cells were transfected with the parental vector
(pMT), generated by excising the 5.2 kb CUX1 cDNA from pMT2-CDP.
Nuclear protein extracts from 1.0×107 transfected HEK293 cells at
48 h post-transfection were subjected to SDS-PAGE and western
blotted with a goat anti-CUX1 primary antibody followed by a secon-
dary anti-goat-HRP antibody. Bound antibody was visualised by ECL
(Fig. 4A). Low level endogenous CUX1 expression was detected in
untransfected HEK293 cells and HEK293 cells transfected with the
parental vector (pMT). In contrast, HEK293 cells transfected with the
CUX1 expressing vector (pMT2-CDP) showed strong CUX1 expression.
Previously identiﬁed isoforms of CUX1were detected including the full
length200 kDaCUX1 (p200), theprocessedhighly active 110 kDaCUX1
(p110) and the 75 kDa CUX1 (p75) (Goulet et al., 2002; Moon et al.,
2001). In addition to these characterised isoforms, additional bands
were identiﬁed at approximately 60 kDa and 40 kDa. These were
prominent only in the pMT2-CDP-transfected cells. To conﬁrm equal
protein loading of each sample, the membrane was also reacted with
antibody to the housekeeping protein GAPDH. GAPDH protein at the
predicted size of 37 kDawas detected at equal intensity for all samples.
Therefore it was concluded that CUX1 protein was successfully over-
expressed in HEK293 cells transfected with a CUX1 expressing vector.
To determine whether CUX1 inﬂuences MIE promoter-driven gene
expression, luciferase reporter assays were performed. HEK293 cells
co-transfected with theMIE regulatory region-driven luciferase vector
(pMIEP), the β-galactosidase expression vector and either the CUX1
expression vector (pMT2-CDP) or its parent vector (pMT) were lysed
and luciferase and β-galactosidase levels were determined. In compa-
rison to the parent pMT, the CUX1 expression vector resulted in a
signiﬁcant decrease in luciferase expression when normalised for
endogenous differences in basal transcription and transfection efﬁ-
ciency using β-galactosidase levels (Fig. 4B). These data demonstrated
that CUX1 repressed activity of the HCMVMIE promoter in transiently
transfected cells.
The transcription factor binding site assay identiﬁed ATCGAT core
sequences from within the HCMV MIE regulatory region as binding
sites for CUX1. To testwhether these binding siteswere responsible for
the observed repression of MIE promoter-driven luciferase expression
by CUX1, the three ATCGATmotifs within the luciferase reporter vector
(represented by oligonucleotides CMV 1, CMV 2 and CMV 4 in the
transcription factor binding assay experiments) were mutated to
TACGAT to generate pMIEPmut. The speciﬁcity of the mutations in
pMIEPmut was conﬁrmed by DNA sequencing. The impact of CUX1 on
luciferase expression driven by this mutated luciferase vector or its
parental luciferase vector was then examined. This analysis revealed
that mutation of these three ATCGAT binding sites for CUX1
signiﬁcantly alleviated the repression observed with the native luci-ferase reporter vector (Pb0.05) (Fig. 4B). A construct which swapped
the A and T at only a single site (encompassed by CMV 1), did not
demonstrate a signiﬁcant alleviation of the repressive effects of CUX1
in comparison to the parental construct (data not shown). These data
demonstrate that the observed repression by CUX1 was mediated at
least in part by the three ATCGAT sequences found within the HCMV
MIE regulatory region represented by oligonucleotides CMV 1, CMV 2
and CMV 4.
To provide additional evidence that the repressive effect of CUX1on
the MIE regulatory region was due to expression of this protein,
HEK293 cellswere transfected as above, except that increasing concen-
trations of CUX1 expression construct (pMT2-CDP) were included,
ranging from 100 ng to 375 ng. In each treatment the total amount of
DNAwas kept constant by altering the amount of parent vector (pMT)
Fig. 5. CUX1 dose-dependent repression of MIE regulatory region-driven gene
expression. HEK293 cells were transfected with a luciferase expression construct
driven by 2.1 kb of the HCMVMIE regulatory region, along with varying amounts of the
CUX1 expression vector or its parent vector pMT. Cells were also transfected with a β-
galactosidase expression vector to normalise between treatments for differences in
transfection efﬁciency and endogenous differences in global transcription. Mean
luciferase values (±SEM) are shown relative to parental vector-transfected cells from
3 independent replicate experiments. Pb0.05, one factor ANOVA.
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were lysed and assessed for luciferase expression, with values norma-
lised using β-galactosidase levels. Addition of increasing amounts of
CUX1 resulted in a signiﬁcant dose-dependent decrease in expression
of luciferase driven from the MIE promoter (Fig. 5) indicating that the
repressive effect observed was due to CUX1 expression.
CUX1 inhibits transcription of viral ie1 and ie2 during HCMV infection
The ability of CUX1 to reduce luciferase reporter expression driven
by the MIE regulatory region suggested that this protein may have a
negative inﬂuence on the expression of the HCMV genes which are
under the control of theMIE regulatory region. To test the effect of CUX1
onMIE gene expression in the context of a virus infection, we sought to
overexpress CUX1 during HCMV infection of HEK293 cells. These cellsFig. 6. Infection of HEK293 cells with HCMV IE2–GFP-tagged virus RC2940. Flow cytometric an
post-infection. The percentage of GFP positive cells at each time point after infection is shoare not fully permissive to HCMV infection, but do support virus entry
and immediate early gene expression (Compton et al., 2003), and so
therefore provide not only a model for transient transfection experi-
ments, but also a model to examine the impact of CUX1 on in vivoMIE
gene expression (i.e. from the virus). To conﬁrm that these cells were
infectable with HCMV, we utilised a GFP-tagged virus RC2940, derived
from HCMV strain Towne. This recombinant virus contains a fusion
between IE2 and GFP, and consequently functions to report on IE2 gene
expression during infection. Cells were exposed to virus at anMOI of 3.
At 2 h P.I. and 48 h P.I., cells were harvested and analysed by ﬂow
cytometry for GFP expression. This analysis showed that between 2 h P.
I. and 48 h P.I. the number of GFP positive HEK293 cells increased from
0.3% to 25%, demonstrating successful infection, and at the very least, a
capacity for de novoMIE gene expression in these cells (Fig. 6).
To determine whether CUX1 was able to inhibit MIE promoter-
driven ie1 and ie2 transcription, HEK293 cells were transfected with
the CUX1 expression construct (pMT2-CDP) or its parent vector (pMT),
followed 48 h later by infectionwith HCMV at anMOI of 3. At 6, 24 and
72 h post-infection, RNA was extracted and subjected to DNase I
digestion and quantitative RT-PCR for CUX1 and viral ie1 and ie2
transcription. Transcript levels for each gene were normalised to two
housekeeping genes GAPDH and LDHA. In a total of 4 independent
replicate experiments, there was a signiﬁcant increase in the
expression of CUX1 transcripts in cells transfected with the CUX1
expressing vector, relative to cells transfectedwith the parental vector.
This overexpression of CUX1 was maintained throughout the time
course of infection, and although there was a decrease in CUX1
expression in pMT2-CDP-transfected cells over time between 6 h to
72 h P.I., this change was not statistically signiﬁcant (PN0.05) (Fig. 7A).
At all three time points post-infection ie1mRNA expression in cells
transfected with the CUX1 expression vector prior to infection with
HCMV was lower than that of parental vector-transfected cells that
had been infected with HCMV in parallel (Fig. 7B). Similarly, CUX1
overexpression reduced the expression of ie2 transcripts at all time
points tested (Fig. 7C). The decrease in both ie1 and ie2 expression by
CUX1 was statistically signiﬁcant at all times post-infection. Thesealysis of HEK293 cells eithermock-infected or RC2940-infected (MOI=3) at 2 h and 48 h
wn.
Fig. 7. Overexpression of CUX1 inhibits ie1 and ie2 transcription during HCMV infection.
HEK293 cells were transfected with a CUX1 expression construct, or its parent vector
pMT, and infected 48 h later with HCMV (MOI=3). At 6, 24 and 72 h post-infection, RNA
extracted from cells was subjected to quantitative RT-PCR for either (A) CUX1, (B) ie1 or
(C) ie2 transcripts. Data were normalised to the mRNA expression by the housekeeping
genes GAPDH and LDHA. Expressions of CUX1, ie1 and ie2 transcripts are shown relative
to parental vector-transfected cells from 4 independent replicate experiments.
Signiﬁcant differences to pMT control were determined using a 1-tailed, paired
Students t-test and are indicated as follows: ⁎Pb0.05, ⁎⁎Pb0.005. Error bars are ±SEM.
Fig. 8. Association of CUX1 with the HCMV MIE region during viral infection by ChIP
assay. HEK293 cells were transfected with a CUX1 expression vector for 48 h before
being exposed to HCMV for 24 h. Cell lysates were analysed by ChIP assay with control
rabbit IgG (Isotype) and anti-CUX1 antibody (α-CUX1), followed by PCR using HCMV
MIE-region primers encompassing the CUX1 binding sites within sequences CMV 1,
CMV 2 and CMV 4. A PCR control was cell lysate with no antibody selection (Input). A
100 bp DNA ladder is shown (Marker).
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expressed by the virus following infection.
CUX1 associates with the MIE regulatory region in vivo
Using the in vitro transcription factor binding assay, three CUX1
binding sites were identiﬁed within the MIE regulatory region. We
therefore sought to determine whether the association of CUX1 to
these three sites occurred in the context of a viral infection using a
chromatin immunoprecipitation (ChIP) assay. HEK293 cells trans-
fected with the CUX1 expressing vector pMT2-CDP for 48 h were
infected with the Toledo strain of HCMV at a MOI of 3 for a period of
24 h. Cross-linked, sonicated chromatin was then subjected to
immunoprecipitation against an anti-CUX1 antibody and a negative
control normal rabbit IgG, followed by PCR using primers which
ﬂanked the 3 CUX1 binding sites identiﬁed earlier by the in vitro
transcription factor binding assay. Strong ampliﬁcation of all 3 regions
was detected following immunoprecipitation with anti-CUX1 anti-
body, but not with the isotype control (Fig. 8). These data provideevidence that CUX1 associates with the MIE regulatory region during
HCMV infection.
Discussion
HCMV replication is dependent on the expression of ie1 and ie2
gene products expressed from theMIE region of the viral genome. The
MIE promoter is controlled by a complex upstream regulatory region
which contains binding sites for a broad range of cellular transcription
factors which act as either activators or repressors of MIE promoter-
driven gene expression (Bain et al., 2003; Hennighausen and
Fleckenstein, 1986; Huang et al., 1996; Hunninghake et al., 1989;
Jeang et al., 1987; Lang et al., 1992; Liu et al., 1994; Sambucetti et al.,
1989; Shelbourn et al., 1989; Zhang et al., 1991; Zweidler-Mckay et al.,
1996). This study provides the ﬁrst evidence that a cellular transcrip-
tion factor CUX1, can bind to sequences from theHCMVMIE regulatory
region in vitro and inhibit MIE promoter activity. Three siteswithin the
MIE regulatory region, all of which contained the binding motif
ATCGAT, were shown to bind to CUX1, and these sites at least partially
accounted for the capacity of CUX1 to repress the MIE promoter. In
addition, overexpression of CUX1 inHCMV-infected cellswas shown to
signiﬁcantly repress ie1 and ie2 mRNA expression by the virus,
suggesting that CUX1 may play a role in modulating the outcome of
HCMV infection.
The demonstration that CUX1binds in vitro and in vivo to sequences
fromHCMV raises the possibility that this transcription factormayplay
a role in other cell types. A study by Meier and Stinski (1997) showed
that in comparison to its parent virus, a virus deleted of the region from
750 bp to 1140 bp upstream of the MIE gene transcriptional start site
displayed very similar, low level ie1 gene expression in a non-
permissive myeloid progenitor cell line THP-1 (Meier and Stinski,
1997). Thus, deletion of this region, which contains one of the three
positive binding sites for CUX1 identiﬁed in our study, does not appear
to be required for the repression of IE gene expression in THP-1 cells.
However, two of the three oligonucleotides found to bind CUX1 in our
studywereoutside this region, andmay therefore represent redundant
functional sites for CUX1 binding and repression. In an analysis of the
repressive capacity of CUX1, Mailly et al. (1996) demonstrated that
repression domains from CUX1 retained the capacity to function even
when bound at a large distance from the transcription initiation site. In
their study, insertion of a 1.6 kb fragment of neutral spacer DNA
between the site of CUX1 repression domain binding and a herpes
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reduction of the repressive effects of CUX1 in comparison to a reporter
construct in which binding occurred immediately adjacent to the
promoter. Thus, CUX1 can exert a repressive effect at a relatively large
distance, which is consistent with a functional role for the CUX1
binding sites we demonstrated as far as 1.2 kb upstream from the MIE
transcription start site.
In an analysis of control of the UL127 promoter, which lies within
the MIE regulatory region, mutations in two other putative CUX1
binding sites at position −650 to −642 and −635 to −627 (relative to the
MIE transcription start site) had little or no effect on UL127 promoter
activity (Lashmit et al., 2004). The impact of these mutations on MIE
promoter activity was not tested in this study, but it remains possible
that additional CUX1 binding sites within the MIE region may play a
biologically important role in the control of MIE gene expression.
Indeed, our ﬁnding that mutation of the three MIE regulatory region
ATCGATsequences only partially abolished CUX1-mediated repression
of the MIE promoter supports the notion that either additional CUX1
binding sites or other regulatory elementsmay be biologically active in
this context and/or that the nature of the mutationwe introduced into
each CUX1 binding site did not result in complete inactivation of CUX1
binding. Extension of these studies to includemore extensivemutation
of ATCGAT sequences, as well as the application of additional
transcription factor binding assay techniques such as electrophoretic
mobility shift assay (EMSA) may help to deﬁne the full repertoire of
CUX1 binding sites which play biologically signiﬁcant roles in
modulatingMIE promoter activity. Recently, Lee et al. (2007) identiﬁed
several regions within theMIE unique region (UR)which could bind to
CUX1, including several which were not identiﬁed in our study. In
addition, they demonstrated that CUX1 overexpression in transiently
transfected HEK293 or 293Tcells repressed expression from the UL127
promoter, but that overexpression of CUX1 did not repress expression
from the MIE promoter. The vector used to assess the impact of CUX1
onMIE promoter activity utilised pRL-CMV (or CMV-R-Luc), which is a
commercially acquired reporter construct with luciferase expression
under the control of HCMV MIE promoter/enhancer sequences.
However, this construct includes only the ﬁrst 735 bp upstream of
the MIE transcriptional start site, and so does not contain the three
ATCGAT sites further upstream which were included in our reporter
construct, and which we identiﬁed as being able to bind to CUX1 to
cause repression of the MIE promoter. The lack of CUX1-mediated
repression of theMIE promoter reported by Lee et al. may therefore be
a consequence of this difference in the reporter constructs used for
these studies.
The full length CUX1 protein contains four distinct DNA binding
domains, at least two of which are required to affect DNA binding.
Three of these DNA binding domains are composed of repeats, termed
Cut repeats (CR) 1–3, while the fourth is a Cut homeodomain (HD).
CUX1 exists in a number of different isoforms which have different
DNA binding characteristics due to the presence or absence of different
combinations of CR1–3 and HD. Full length CUX1, p200, exhibits rapid
but transient binding that seems tomake use of the CR1CR2, while the
proteolytically cleaved p110 and p90 isoforms contain CR2CR3HD, and
p75 contains CR3HD, each appear to be capable of bindingmore stably
than the full length protein. It remains to be determined which CUX1
isoforms bind to theMIE region, as we detected expression of multiple
isoforms in the transfected HEK293 cells used in our binding studies.
Our western blot analysis also detected a number of smaller products
which may be additional CUX1 isoforms expressed in HEK293 cells. It
is not clear if these proteins contain DNA binding domains or if they
have any role in the observation reported in this study.
CUX1 exhibits some ﬂexibility in its sequence requirements for
binding (Nepveu, 2001). The main consensus binding site for p110 is
ATCGAT, and this palindromic motif mediates stable DNA binding by
CR2,CR3 and the HD. Full length CUX1 binding appears to be mediated
by CGAT or CAAT repeats. Interestingly this ATCGAT motif is similar toa R1motif that occurs 16 timeswithin themodulator region of theMIE
regulatory region, TATCG (Huang et al., 1996; Meier and Stinski, 1997;
Thrower et al., 1996). Huang and co-workers have shown that an MIE
motif pair, ATCG-N6-CGAT, strikingly similar to the motifs that bound
CUX1, was able to bind a protein that repressed transcription driven by
the MIE promoter in undifferentiated THP-1 cells, and that this phe-
notype was absent in differentiated THP-1 cells (Huang et al., 1996).
While Huang et al. (1996) did not report identiﬁcation of the protein
responsible, this motif pair is similar to the motifs that are bound by
full length CUX1 p200 or the p110 isoform, suggesting that this
repressionmay have beenmediated by CUX1. Bullock et al. (2002) also
found that the R1 element was bound by a protein that is antigenically
similar to Drosophila BEAF-32 (Bullock et al., 2002). Interestingly, the
CUX1 consensus binding site matches that reported for BEAF-32
(Orian et al., 2003), further supporting the notion that the R1 repeat
element may contain an active binding site for CUX1.
CUX1 has been shown to repress viral gene expression or repli-
cation of viruses such as human papilloma virus andmousemammary
tumor virus by binding to critical viral regulatory sequences (Ai et al.,
1999; Narahari et al., 2006; O'Connor et al., 2000; Pattison et al., 1997;
Sato et al., 2007; Zhu and Dudley, 2002; Zhu et al., 2000), although the
mechanism of repression by CUX1 has not been fully elucidated. CUX1
has also been shown to bind to adenovirus packaging sequences,
where it may play a role in viral DNA packaging (Erturk et al., 2003).
One mode by which CUX1 is capable of repressing transcription is by
recruiting HDACs thereby facilitating the formation of heterochroma-
tin (Li et al., 1999; Mailly et al., 1996). As CUX1 is a transcriptional
repressor which is expressed in myeloid cells, and during latent
infection of myeloid cells the MIE region is associated with markers of
transcriptional inactivity such as non-acetylated histones and hetero-
chromatin protein 1 (Murphy et al., 2002; Reeves et al., 2005), it is
tempting to speculate that CUX1 may be a factor contributing to
HCMV latency in these cells. Moreover, CUX1 is capable of recruiting
HDACs (Li et al., 1999), and the activity of CUX1 is down-modulated at
terminal stages of myeloid differentiation to macrophages (Martin-
Soudant et al., 2000; Marziali et al., 1999), when these cells can
become permissive to HCMV replication, further correlating with a
possible role of this transcription factor during HCMV latency or
reactivation.
CUX1 is an important transcription factor involved in both cellular
differentiation and cell cycle control (Bodmer et al., 1987; Coqueret et
al., 1998; Vanden Heuvel et al., 1996). Our experiments showing that
CUX1 reduces MIE gene expression during virus infection do not rule
out the possibility that global effects of CUX1 on host cell gene expres-
sion may have indirect effects on viral gene expression. However, our
data providing evidence that CUX1 may bind to sequences found
within theMIE regulatory region, togetherwith ourdemonstration of a
reduction of MIE promoter-driven gene expression in transient co-
transfection experiments suggests that the effects of CUX1onMIE gene
expression during virus infection are likely to be speciﬁc.
Assessing the impact of CUX1 on the expression of other viral genes,
the potential for recovery of MIE repression if CUX1 levels drop in
infected cells, and determining whether CUX1 repression of MIE gene
expression inhibits virus replication following infection of fully per-
missive cell types will be important components of future studies to
determine the role of CUX1 in regulating permissiveness to productive
infection.While our initial assessment of infected, fully permissive HFFs
indicated no signiﬁcant changes in CUX1 mRNA levels compared with
mock-infected cells (data not shown), examination of CUX1 function in
this cell type will be required to determine the extent of any impact on
the full virus replicative cycle. Similarly, as monocytes and hemato-
poietic progenitor cells are a reservoir for latent infection, extension of
this work to include analysis of CUX1 expression and function in
primary myeloid lineage cells in the context of HCMV latent infection
and reactivation and cellular differentiation state will be important to
determine whether this transcription factor regulates viral latency.
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Cells and virus
Human embryonic kidney 293 (HEK293) cells (ATCC #CRL-1573)
and human foreskin ﬁbroblast cells (HFFs) were maintained in
Dulbecco's modiﬁed Eagle's medium (DMEM) containing 10% fetal
calf serum (FCS) at 37 °C with 5% CO2. HCMV RC2940 is an IE2 green
ﬂuorescent protein (GFP)-tagged virus prepared from a plaque-
puriﬁed derivative of the TownevarRIT3 strain of HCMV.
To construct RC2940, plasmid pON2940 was ﬁrst constructed as
follows: A 6.7 kb SalI-EcoRI IE-region fragment fromplasmid pON303G
(Cherrington and Mocarski, 1989) was ligated between the SalI and
EcoRI sites of pGEM3zf(+) (Promega) to produce plasmid pON2903.
pON2903 was PCR-ampliﬁed with primer primer ie p4 (5′-TCCTTTCA-
AGGTGATCASTCAAACCGCCCGTGCCT-3′) and primer ie p7 (5′-
GGATCCCTGAGACTTGTTCCTCAG-3′). PCR products were T/A cloned
into pGEMT-easy (Promega) to produce pON2937. pON2903 was PCR-
ampliﬁed with primer sp6 (5′-ATTTAGGTGACACTATAG-3′) and primer
ie p8 (5′-GGATCCTAAGTGAAAAACTGGAAAG-3′). PCR products were T/
A cloned into pGEMT-easy (Promega) to produce pON2938. pGFP-mut2
(Cormack et al., 1996) was PCR-ampliﬁed with primer GFP Bam 5′ (5′-
GGATCCATGAGTAAAGGAGAAGA-3′) and primer GFP 3′ (5′-GGATCCC-
TATTTGTATAGTTCATC-3′). PCR products were T/A cloned into pGEMT-
easy (Promega) to produce pON2939. A 700 bp BamHI/PstI from
pON2937 and a 1000 bp BamHI/SphI from pON2938 were ligated into
the PstI and SphI sites of pGEMT-easy (Promega) to make pON2941. A
712 bpBamHI fragment frompON2939was ligated into the BamHI site of
pON2941 to make pON2942. A 1.4 kb SfI/SalI fragment from pON2942
was ligated into the SfI/SalI site of pON2903 tomakepON2940.HFFswere
then electroporated with 20 μg of EcoRI/SalI-linearized pON2940. Cells
were then seeded into two T25 ﬂasks, incubated overnight and then
infected with HCMV CR208 virus at a multiplicity of infection (MOI) of 5.
CR208 is a Towne-derived ie1-defective virus which exhibits a major
growth defect at low MOIs (Greaves and Mocarski, 1998). After 7 days,
supernatant was collected and progeny virus titers were determined on
ie1-expressing ihﬁe1.3 cells (Greaves and Mocarski, 1998). To enrich
rescued viruses (whichwould now contain the IE2–GFP fusion), progeny
virus was used to infect HFFs at an MOI of 0.1 and supernatant viruses
were harvested at 100% cytopathic effect (CPE). To purify RC2940 virus,
three rounds of plaque puriﬁcation were performed using HFFs overlaid
with 0.5% agarose. The nature of the fusion was conﬁrmed by DNA
sequencing. RC2940 expresses high levels of GFP during productive
infection of HFFs, with virus titers and plaquing efﬁciency comparable to
that of the parental TownevarRIT3 strain of HCMV (J. Xu, D. Formankova,
and E. S. Mocarski, unpublished results).
Expression vectors
pMIEP is a luciferase reporter construct produced by excising a
2.1 kbp section of the HCMV genomic sequence encompassing theMIE
regulatory region (positions +100 to −2000 with respect to the start of
MIE gene transcription). This fragment was directionally cloned into
the pGL3-Basic vector (Promega) such that luciferase expression is
driven by the MIE promoter. The three ATCGAT binding sites within
the MIE regulatory region of in construct pMIEP were mutated using
the Stratagene Quick Change II site directed mutagenesis kit to gene-
rate the construct pMIEPmut. Primers used to construct the mutations
were: CMV1_F: CAATATTGATTCAATGTATATTACGATATGCATTGGC-
CATGTG; CMV1_R: CACATGGCCAATGCATATCGTAATATACATTGAAT-
CAATATTG; CMV2_F: CCAGGTTGATCCTACGATAGGGAGCG; CMV2_R:
CGCTCCCTATCGTAGGATCAACCTGG; CMV4_F: CAATATGCCATACTTT-
CAAATTACGATTTGTCCAATATCGCC; and CMV4_R: GGCGATATTGGA-
CAAATCGTAATTTGAAAGTATGGCATATTG. pMT2-CDP is a construct
expressing human CUX1 protein consisting of a 5.2 kb full length
CUX1 cDNA under the control of the major adenovirus late promoterand kindly provided by Dr Ellis Neufeld of the Children's Hospital,
Boston (Neufeld et al., 1992). pMT is a derivative of pMT2-CDP,
prepared by excising the 5.2 kb cDNA expressing the full length CUX1
protein. pSV is a β-galactosidase expressing construct (Promega)
driven by the SV40 early promoter and enhancer and was used as an
internal control to normalise transfection efﬁciency.
Transient transfections and luciferase assays
For transient transfections, six well transfection plates were seeded
with HEK293 cells in DMEM with 10% FCS and at 80% conﬂuency, each
well was co-transfected with 750 ng of the pMIEP reporter construct,
250 ng of the pSV construct and 1 μg of either pMT2-CDP or pMT
constructs using 6 μl of Fugene 6 (Roche) in 100 μl of DMEM per well.
After 48 h of expression, cells were lysed and assayed using the
manufacturer's protocols of the Dual-Light Assay (Applied Biosystems).
Nuclear protein extraction and western blot analysis
To extract nuclear proteins for the western blot, 1.5 ml of a solution
containing 10 mM HEPES (pH 7.9), 15 mM KCl, 2 mM MgCl2, 0.1 mM
EDTA, dH2O and protease inhibitor cocktail was added to 107 HEK293
cells. After 10 min incubation on ice, 25 μl of 0.2% NP-40 was added
followed by brieﬂy vortexing and centrifuging at 20,000 ×g for 10 s.
The nuclear pellet was then washed once in the above solution before
being resuspended in 100 μl of a solution containing 50mMHEPES (pH
7.9), 50 mM KCl, 0.1 mM EDTA, dH2O and protease inhibitor cocktail.
This was followed by the addition of 100 μl of a solution containing
50 mM HEPES (pH 7.9), 0.8 M KCl, 0.1 mM EDTA, dH2O and protease
inhibitor cocktail. The mixture was then incubated for 30 min at 4 °C
and centrifuged at 20,000 ×g for 10 min. The supernatant containing
the nuclear extracts was then used for the western blot analysis.
Samples were boiled for 10 min in the presence of Reducing Agent
(Biorad) and nuclear extracts subjected to SDS-polyacrylamide gel
electrophoresis (SDS-PAGE). Proteins were transferred to PVDF
membrane and stained with 0.1% amido black. The membrane was
then incubated overnight at 4 °C in a blocking solution containing TBS
(200 mM Tris base, 1.4 M NaCl, pH 7.6) with 5% skimmilk powder. The
membrane was then reacted with a CUX1 speciﬁc antibody (C-20,
Santa Cruz Biotechnology) diluted 1:400 in blocking solution for 1 h at
room temperature. The membrane was then washed three times for
5 min in TBS–T (TBS and 0.1% Tween), followed by one wash with TBS
for 2 min. To detect speciﬁc binding to CUX1 protein, a secondary
antibody of anti-goat-HRP (Dako) diluted 1:4000 in blocking solution
was added to the membrane and incubated for 30 min at room
temperature, followed by the above wash steps. Bound antibody was
detected with enhanced chemiluminescence (ECL) (Amersham Bios-
ciences) and exposure to X-ray ﬁlm.
To reprobe the membrane, it was ﬁrst stripped by soaking in a
solution containing 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM
Tris–HCl (pH 6.7) for 30 min at 70 °C with gentle agitation. The mem-
brane was then washed twice in TBS–T and once in TBS. The house-
keeping gene GAPDH was detected using an antibody speciﬁc to
GAPDH (Santa Cruz Biotechnology) diluted 1:1000 in blocking
solution. This was followed by a secondary antibody of anti-rabbit-
HRP (Dako) diluted 1:12000 in blocking solution. Bound antibody was
detectedwith ECL (AmershamBiosciences) and exposure to X-ray ﬁlm.
In vitro transcription factor binding assay
The in vitro transcription factor binding assay was performed using
the Novagen NoShift Transcription Factor Assay Kit (Merck KGaA). Brief-
ly, biotinylated oligonucleotides (Sigma-Proligo) were re-annealed by
adding 10 μg of sense and anti-sense strands with 100 μl of 0.5x SCC
(Sigma) which was then heated for 10 min at 100 °C and diluted to a
concentration of 10 pmol/μl. A mixture consisting of 5 μl 4x NoShift
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DNA, 5 μl of nuclear extract and 7 μl of nuclease-free H2O was prepared
and added to 1 μl of the double-stranded biotinylated oligonucleotide
followed by incubation on ice for 30 min. Two human consensus
CUX1 binding sequences were included as positive controls: POS 1
(5′-TCGAGACGATATCGATAAGCTTCTTTTC) (Moon et al., 2001) and POS 2
(5′ GGGATCGATCTGGAACTCCGGGATCGATCTGGAACTCC) (Nirodi et al.,
2001). Sequences tested for CUX1 binding within the HCMV MIE
region upstream of the transcription site (nucleotide position +1) were
CMV 1, which was located at position −738 to −759 (5′-TTCAA-
TGTATAGATCGATATGCA); CMV 2, position −1246 to −1268 (5′-CCAGGT-
TGATCCATCGATAGGGA); CMV 3, position −219 to −247 (5′-CCAT-
GGTAATAGCGATGACTAATACGTAG); CMV 4, position −1007 to −1035
(5′-ATTTTCAAATATCGATTTTTCCAATATCG); CMV 5, position −1030 to
−1058 (5′-ATATCGCCATCTCTATCGGCGATAAACAC); CMV6, position
−697 to −725 (5′-TATATAACCAATGAATAATATGGCTAATG); CMV7, posi-
tion −436 to −464 (5′-TATGGGAACATACGTCATTATTGACGTCA); CMV8,
position −180 to −208 (5′-GCTATCCACGCCCATTGATGTACTGCCAA). A
sequence located +118 to +138 downstream of the transcription start
site with no predicted CUX1 binding site, NEG (5′-TCTATAGGCGG-
TACTTACGTC), was included as a negative control. Sequences used for
mutation studies consisted of parent sequences with the A and T
nucleotides swapped at the predicted core CUX1 binding site as
indicated by the underlines: CMV 1Mut (5′-TTCAATGTATAGTACGA-
TATGCA); CMV 2Mut (5′-CCAGGTTGATCCTACGATAGGGA); CMV 4Mut
(5′-ATTTTCAAATATCGTATTTTCCAATATCG). The mixtures were then
added to a freshly prepared Streptavidin coated 96 well plate.
Following incubation for 1 h at 37 °C, wells were washed three
times with washing buffer and 100 μl of the goat anti-CUX1 antibody
(C-20, Santa Cruz Biotechnology) was added diluted to 1:500 in the
antibody dilution buffer. Following 1 h incubation and three washes
with washing buffer, 100 μl of a secondary anti-goat-HRP antibody
(Dako) was added at 1:1000 dilution. The plate was then incubated for
30 min at 37 °C before being washed ﬁve times in washing buffer.
100 μl of TMB substrate was then added to each well and incubated in
the dark at room temperature for 30 min. The reaction was stopped
by adding 100 μl of 1 M HCl. The absorbance for each well was
measured at 450 nm with a luminometer within 30 min.
RNA extraction and quantitative RT-PCR
RNA extractions were carried out according to the manufacturer's
instructions using Ambion's RNAqueous kit (Ambion). Eluted RNAwas
precipitatedwith0.1volumesof 5Mammoniumacetate and3volumes
of 100% ethanol. The precipitated RNA was quantitated using a
Bionalayser (Agilent Technologies). RNA was then treated with RQ1
DNase I (Promega) followed by reverse transcription with random
hexamers using SuperScript III reverse transcriptase (Invitrogen). Re-
moval of RNA complementary to the cDNA was achieved by adding
2 units of RNase H (Invitrogen) and incubating at 37 °C for 20 min.
PCRwas carriedout usingSYBRGreenERqPCRSuperMix (Invitrogen)
in a Stratagene Mx3005P qPCR machine. The PCR reaction thermal
proﬁle was as follows: 1 × cycle: 2 min at 50 °C, 2 min at 95 °C; 50 ×
cycles: 15 s at 95 °C, 45 s at 45 °C; 1 × cycle: 1 min at 95 °C, 30 s at 55 °C,
30 s at 95 °C. Two housekeeping genes GAPDH and LDHAwere included
to assess relative changes in gene expression between the different
treatments. The ampliﬁcation efﬁciencies for each primer pair were
determined by creating standard curves with 10-fold serial dilutions of
pooled cDNA samples. The log of the relative target quantitywas plotted
versus the cycle threshold (CT) values. A dissociation curve was gene-
rated for each primer pair to demonstrate the ampliﬁcation of a single
product. All primers were designed using the Primer3 website (http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The sequences
used for primers were as follows: GAPDH-F: 5′TCACCAGGG-
CTGCTTTTAAC, GAPDH-R: 5′GACAAGCTTCCCGTTCTCAG; LDHA-F: 5′
TGGGAGTTCACCCATTAAGC, LDHA-R: 5′AGCACTCTCAACCACCTGCT;CUX1-F: 5′TGTCCAGCTACCCACCTCTC, CUX1-R: 5′CCCACCT-
CATTTTTCACCTG; IE1: IEP3G: 5′CAATACACTTCATCTCCTCGAAAGG, IEP4-
BII: 5′TATGTGTTGTTATCCTCCTCTACAG; IE2: IEP5E-F: 5′GGAGCCT-
CAAAGAATTGCAC, IEP5E-R: 5′CCTGGTTGGTGGAGAAGATG.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed using the EZ-ChIP kit following the
manufacturer's protocol (Millipore). Chromatin was obtained from
HEK293 cells transfected with pMT2-CDP for 48 h and infected for 24 h
with the Toledo strain of HCMV at anMOI of 3. The chromatin of 1×106
cells was then sonicated to DNA sizes of between 200 bp and 1000 bp
and used for each immunoprecipitation with normal rabbit IgG
(Millipore) or rabbit anti-CUX1 antibodies (M-222, Santa Cruz Biotech-
nology). M-222 is a polyclonal antibody that recognizes amino acids
1111–1332 mapping at the C-terminus of CUX1 of mouse origin.
Immunoprecipitated DNA was analysed by PCR using primers speciﬁc
to theMIE region (CMV1_F: 5′-CAATAGCCAATATTGATTTATGC, CMV1_R:
5′GCGATTCTGTGTGTCGCAAA; CMV2_F: 5′ATTTGCGACACACAGAATCG,
CMV2_R: 5′CGCGATAGTGGTGTTTATCG; CMV4_F: 5′CGCTCTCCAGGTA-
CTGATCC, CMV4_R: 5′CCCCTCCGTGTTGTAGGTTA).
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